Gilead Sciences

Gilead Sciences μετάφραση στα ελληνικά

HIV/AIDS

			Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.GileadHIV.com	More
			Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) is the first once-daily single tablet regimen (STR) for HIV-1 infection intended as a stand-alone therapy or in combination with other antiretrovirals. The product combines Sustiva® (efavirenz), manufactured by Bristol-Myers Squibb Company, and Truvada® (emtricitabine and tenofovir disoproxil fumarate), manufactured by Gilead Sciences. Atripla was cleared for marketing in the United States in July 2006. Atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals. Atripla, Truvada, Viread and Emtriva are not indicated for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of these drugs have not been established in patients co-infected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Emtriva or Viread (components of Atripla and Truvada). Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue Atripla, Truvada, Emtriva or Viread and are co-infected with HIV and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted. Click here for full prescribing information (PDF), including details about indication and usage and important safety information. For Prescribing Information outside the United States, please contact our medical information department at 1-800-GILEAD-5 (1-800-445-3235), Option 2, or email Medical Information Request Form. Marketing Partners Bristol-Myers Squibb Company -- U.S. and Canada Merck & Co, Inc. -- Developing World

			Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.GileadHIV.com	More
			Emtriva® (emtricitabine) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients over three months of age. This indication is based on the analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies of 48 weeks duration in antiretroviral-naïve and antiretroviral-experienced patients who were virologically suppressed on an HIV-treatment regimen. In treatment-experienced patients, the use of Emtriva may be considered for patients with HIV strains that are expected to be susceptible to Emtriva as assessed by genotypic or phenotypic testing. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals. Emtriva is not indicated for the treatment of chronic hepatitis B virus infection and the safety and efficacy of Emtriva have not been established in patients co-infected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Emtriva. Hepatic function should be monitored closely with both clinical and laboratory follow-up at least several months in patients who discontinue Emtriva and are co-infected with HIV and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted. Click here for full prescribing information (PDF), including details about indication and usage and important safety information. For Prescribing Information outside the United States, please contact our medical information department at 1-800-GILEAD-5 (1-800-445-3235), Option 2, or email Medical Information Request Form. Marketing Partner Japan Tobacco Inc. -- Japan

			Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.GileadHIV.com	More
			Truvada® (emtricitabine and tenofovir disoproxil fumarate) is a once-daily fixed-dose combination of two nucleoside reverse transcriptase inhibitors, Viread® (tenofovir disoproxil fumarate) and Emtriva® (emtricitabine). Truvada was cleared for marketing in the United States in August 2004 and in Europe in February 2005. In the United States, Truvada is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1 infection in adults. It is not recommended that Truvada be used as a component of a triple nucleoside regimen. Truvada should not be co-administered with Atripla™, Emtriva, Viread or lamivudine-containing products. In treatment experienced patients, the use of Truvada should be guided by laboratory tests and treatment history. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals. Truvada is not approved for the treatment of chronic hepatitis B virus (HBV) infections and the safety and efficacy of Truvada have not been established in patients coinfected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Emtriva or Viread, the components of Truvada. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HIV and HBV and discontinue Truvada. If appropriate, initiation of anti-hepatitis B therapy may be warranted. Click here for full prescribing information (PDF), including details about indication and usage and important safety information. For Prescribing Information outside the United States, please contact our medical information department at 1-800-GILEAD-5 (1-800-445-3235), Option 2, or email Medical Information Request Form. Marketing Partner Japan Tobacco Inc. -- Japan

			Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.GileadHIV.com	More
			Viread® (tenofovir disoproxil fumarate) is a once-daily nucleotide analog HIV-1 reverse transcriptase and HBV polymerase inhibitor. Viread was cleared for marketing in the United States in October 2001 and in Europe in February 2002. The European Commission approved Viread for chronic hepatitis B (HBV) in April 2008, and the U.S. Food and Drug Administration (FDA) approved Viread for chronic hepatitis B in adults in August 2008. In the United States, Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults, and is also indicated for the treatment of chronic hepatitis B in adults. Viread should not be used in combination with Truvada® or Atripla™. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals. Severe acute exacerbations of hepatitis have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including Viread. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including Viread. If appropriate, resumption of anti-hepatitis B therapy may be warranted. Click here for full prescribing information (PDF), including details about indication and usage and important safety information. For Prescribing Information outside the United States, please contact our medical information department at 1-800-GILEAD-5 (1-800-445-3235), Option 2, or email Medical Information Request Form. Marketing Partner Japan Tobacco Inc. -- Japan

Liver Disease

			Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.Hepsera.com	More
			Hepsera® (adefovir dipivoxil) is a once-daily, orally-administered nucleotide analogue reverse transcriptase inhibitor for the treatment of patients with chronic hepatitis B. Hepsera was approved in the United States in September 2002 and in Europe in March 2003. In the United States, Hepsera is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis B therapy including Hepsera. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis b therapy. If appropriate, resumption of anti-hepatitis b therapy may be warranted. In patients at risk of or having underlying renal dysfunction, chronic administration of Hepsera may result in nephrotoxicity. These patients should be monitored closely for renal function and may require dose adjustment. HIV resistance may emerge in chronic hepatitis B patients with unrecognized or untreated human immunodeficiency virus (HIV) infection treated with anti-hepatitisB therapies, such as therapy with Hepsera, that may have activity against HIV. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals. Click here for full prescribing information (PDF), including details about indication and usage and important safety information. For Prescribing Information outside the United States, please contact our medical information department at 1-800-GILEAD-5 (1-800-445-3235), Option 2, or email Medical Information Request Form. Marketing Partner GlaxoSmithKline Inc. -- Asia, Latin America

			Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.Viread.com	More
			Viread® (tenofovir disoproxil fumarate) is a once-daily nucleotide analog HIV-1 reverse transcriptase and HBV polymerase inhibitor. Viread was cleared for marketing in the United States in October 2001 and in Europe in February 2002. The European Commission approved Viread for chronic hepatitis B (HBV) in April 2008, and the U.S. Food and Drug Administration (FDA) approved Viread for chronic hepatitis B in adults in August 2008. In the United States, Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults, and is also indicated for the treatment of chronic hepatitis B in adults. Viread should not be used in combination with Truvada® or Atripla™. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals. Severe acute exacerbations of hepatitis have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including Viread. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including Viread. If appropriate, resumption of anti-hepatitis B therapy may be warranted. Click here for full prescribing information (PDF), including details about indication and usage and important safety information. For Prescribing Information outside the United States, please contact our medical information department at 1-800-GILEAD-5 (1-800-445-3235), Option 2, or email Medical Information Request Form. Marketing Partner Japan Tobacco Inc. -- Japan

Cardiovascular

			Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.Letairis.com	More
			Letairis® (ambrisentan) is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Letairis can cause elevation of liver aminotransferases (ALT and AST) to at least 3 times the upper limit of normal (ULN). Letairs treatment was associated with aminotransferase elevations >3 x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including long-term open-label trials out to one year. One case of aminotransferase elevations >3 x ULN has been accompanied by bilirubin elevations >2 x ULN. Because these changes are a marker for potentially serious liver injury, serum aminotransferase levels (and bilirubin if aminotransferase levels are elevated) must be measured prior to initiation of treatment and then monthly. In the post-marketing period with another endothelin receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic cirrhosis were reported after prolonged (>12 months) therapy. In at least one case with bosentan, a late presentation (after >20 months of treatment) included pronounced elevations in aminotransferases and bilirubin levels accompanied by non-specific symptoms, all of which resolved slowly over time after discontinuation of the suspect drug. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment. Elevations in aminotransferases require close attention. Letairis should generally be avoided in patients with elevated aminotransferases (>3 x ULN) at baseline because monitoring liver injury may be more difficult. If liver aminotransferase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin >2 x ULN, treatment should be stopped. There is no experience with the re-introduction of Letairis in these circumstances. CONTRAINDICATION: PREGNANCY Letairis is very likely to produce serious birth defects if used by pregnant women, as this effect has been seen consistently when it is administered to animals [see Contraindications (4.1) contained in the full prescribing information]. Pregnancy must therefore be excluded before the initiation of treatment with Letairis and prevented thereafter by the use of at least two reliable methods of contraception unless the patient has had a tubal sterilization or Copper T 380A IUD or LNg 20 IUD inserted, in which case no other contraception is needed. Obtain monthly pregnancy tests. Because of the risks of liver injury and birth defects, Letairis is available only through a special restricted distribution program called the Letairis Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only prescribers and pharmacies registered with LEAP may prescribe and distribute Letairis. In addition, Letairis may be dispensed only to patients who are enrolled in and meet all conditions of LEAP [see WARNINGS, Prescribing and Distribution Program for Letairis contained in the full prescribing information]. Marketing Partner GlaxoSmithKline Inc. – Outside U.S.

			Visit www.Lexiscan.com	More
			Lexiscan® (regadenoson) injection is the first A2A adenosine receptor agonist approved by the FDA (in April 2008) for use as a pharmacologic stress agent in radionuclide MPI studies. The product has been designed to target the A2A adenosine receptor, which is the adenosine receptor subtype responsible for coronary vasodilation. Important Safety Information Do not administer Lexiscan to patients with second- or third-degree AV block or sinus node dysfunction unless these patients have a functioning artificial pacemaker. Fatal cardiac arrest, life-threatening ventricular arrhythmias, and myocardial infarction may result from the ischemia induced by pharmacologic stress agents. Cardiac resuscitation equipment and trained staff should be available before administering Lexiscan. Adenosine receptor agonists, including Lexiscan, can depress the SA and AV nodes and may cause first-, second-, or third-degree AV block, or sinus bradycardia. In postmarketing experience, heart block (including third degree), and asystole within minutes of Lexiscan administration have occurred. Adenosine receptor agonists, including Lexiscan, induce arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with cardiac or cerebrovascular insufficiency. Decreased systolic blood pressure (>35 mm Hg) was observed in 7% of patients and decreased diastolic blood pressure (>25 mm Hg) was observed in 4% of patients within 45 minutes of Lexiscan administration. Adenosine receptor agonists, including Lexiscan, may cause bronchoconstriction and respiratory compromise. For patients with known or suspected bronchoconstrictive disease, chronic obstructive pulmonary disease (COPD), or asthma, appropriate bronchodilator therapy and resuscitative measures should be available prior to Lexiscan administration. The most common adverse reactions (≥5%) to Lexiscan are dyspnea, headache, flushing, chest discomfort, angina pectoris or ST-segment depression, dizziness, chest pain, nausea, abdominal discomfort, dysgeusia, and feeling hot. Most adverse reactions began soon after dosing, and generally resolved within approximately 15 minutes, except for headache, which resolved in most patients within 30 minutes. Lexiscan overdosage may result in serious reactions. Aminophylline was used as a reversal agent in 3% of patients. Please visit www.Lexiscan.com for Full Prescribing Information. Marketing Partner Astellas Pharma Inc. -- U.S.

			Download Full U.S. Prescribing Information, including Important Safety InformationVisit www.Ranexa.com	More
			Ranexa® (ranolazine) is an extended-release tablet for the treatment of chronic angina. Ranexa was approved in the United States in January 2006. In 2008, the Ranexa indication was expanded in the United States to include first-line treatment for chronic angina. The product was approved in Europe in August 2008. Important Safety Information Ranexa (ranolazine extended-release tablets) is a prescription medicine used to treat adults with chronic angina. Do not take Ranexa if you are taking certain medicines, such as: Nizoral® (ketoconazole), Sporanox® (itraconazole), Biaxin® (clarithromycn), Serzone® (nefazodone), Viracept® (nelfinavir), Norvir® (ritonavir), Crixivan® (indinavir), Fortovase® (saquinavir), Rifadin® (rifampin), Mycobutin® (rifabutin), Priftin® (rifapentin), phenobarbital, Phenytek® (phenytoin), Tegretol® (carbamazepine), or the herbal supplement St. John's Wart. Do not take Ranexa if you have serious liver problems. Tell your doctor if you or a family member has had problems with your heart rhythm or heartbeat (such as QTc prolongation). While Ranexa can be taken with other common prescription drugs for conditions such as heart disease, it is still important to tell your doctor and pharmacist about all the prescription medications and herbal supplements you take. If you take Ranexa, you should limit the amount of grapefruit juice or grapefruit products you consume. The most common side effects of Ranexa include dizziness, headache, constipation, or nausea. You should know how you react to Ranexa before operating an automobile or machinery, or engaging in activities requiring mental alertness or coordination. Tell your doctor if you faint or have a side effect that bothers you or does not go away. If you have any questions about your conditions or your treatment, including Ranexa, talk with your doctor. Please visit www.Ranexa.com for Full Prescribing Information. Marketing Partner Menarini Group -- EU

Respiratory

			Visit www.Tamiflu.com	More
			Tamiflu® (oseltamivir phosphate) is the first neuraminidase inhibitor in pill form for the treatment and prevention of influenza A and B. Tamiflu was cleared by the U.S. FDA for the treatment of influenza in October 1999, for the prevention of influenza in November 2000, and for the treatment of children one year and older in December 2000. Tamiflu was approved in Europe in June 2002. The most common side effects that occurred in patients taking Tamiflu were nausea and vomiting. Taking Tamiflu with food may reduce the potential of these side effects. Please visit www.Tamiflu.com for Full Prescribing Information. Marketing Partner F. Hoffmann-La Roche Ltd -- Worldwide

Other

			Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.AmBisome.com	More
			AmBisome® (amphotericin B) liposome for injection is a treatment for life-threatening, systemic fungal infections. AmBisome was cleared for marketing in the United States in 1997, and first cleared for marketing in Europe in 1990. In the United States, AmBisome is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV- infected patients. Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites. AmBisome is contraindicated in those patients who have demonstrated or have known hypersensitivity to amphotericin B or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk. Anaphylaxis has been reported with amphotericin B and other amphotericin B-containing drugs, including AmBisome. If a severe anaphylactic reaction occurs, the infusion should be discontinued immediately and the patient should not receive further infusions of AmBisome. Click here for full prescribing information (PDF), including details about indication and usage and important safety information. For Prescribing Information outside the United States, please contact our medical information department at 1-800-GILEAD-5 (1-800-445-3235), Option 2, or email Medical Information Request Form. Marketing Partners Astellas Pharma Inc. -- U.S. and Canada Dainippon Sumitomo Pharma Co., Ltd. -- Japan

			Visit www.MACUGEN.com	More
			Macugen® (pegaptanib sodium injection) was approved by the FDA on December 17, 2004 for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision. Macugen is a pegylated anti-VEGF aptamer, a single strand of nucleic acid that binds with specificity to a particular target. Macugen specifically binds to VEGF 165, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the primary pathological processes responsible for the vision loss associated with neovascular AMD. Macugen is administered in a 0.3 mg dose once every six weeks by intravitreal injection. In the United States, Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration. The most frequently reported adverse events in patients treated with Macugen 0.3mg for up to two years were anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure, ocular discomfort, punctuate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities. These events occurred in approximately 10-40% of patients. Please visit www.Macugen.com for Full Prescribing Information. Marketing Partner OSI Pharmaceuticals, Inc. -- U.S. Pfizer Inc. -- Outside U.S.

Download Full U.S. Prescribing Information, includi

Email: corporate_development@gilead.com Mail: Gilead Sciences Attn: Corporate Development Department 333 Lakeside Drive Foster City, CA 94404 Advancing Therapeutics, Improving Lives Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases. Gilead’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. Our portfolio of 12 marketed products includes a number of category firsts and market leaders, including Atripla® (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) - the first single-tablet regimen for HIV infection. The company's latest therapy, Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B, was approved in August 2008. Chronic hepatitis B, a serious liver disease caused by the hepatitis B virus, is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States. More Than 20 Years of Growth Gilead was founded in 1987 in Foster City, California. In just over 20 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of investigational drugs and approximately 4,000 employees. In 2008, Gilead’s annual revenues surpassed $5.3 billion. BusinessWeek has ranked Gilead #1 in its 2009 listing of the 50 best-performing companies, up from #2 last year. Our Marketed Products Following is a summary of Gilead's product portfolio. See our Products section for full prescribing information, including BOXED WARNINGS and Important Safety Information. HIV/AIDS Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is the first and only once-daily single tablet regimen for the treatment of HIV infection in adults. It is intended for use as a stand-alone therapy, or in combination with other antiretrovirals, and combines Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) with Sustiva® (efavirenz), manufactured by Bristol-Myers Squibb. (U.S. approval, 2006; E.U. approval, 2007.) Emtriva® (emtricitabine) is a once-daily oral nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva is also available as an oral solution for use in pediatric patients. (U.S. and E.U. approval, 2003.) Truvada® (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose once-daily combination pill containing Viread® and Emtriva®. It is used in combination with other antiretroviral agents for the treatment of HIV infection in adults. (U.S. approval, 2004; E.U. approval, 2005.) Viread® (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV infection in adults in combination with other antiretroviral agents. (U.S. approval, 2001; E.U. approval, 2002.) Liver Disease Hepsera® (adefovir dipivoxil) is a once-daily, oral NtRTI for the treatment of patients with chronic hepatitis B. (U.S. approval, 2002; E.U. approval, 2003.) Viread® (tenofovir disoproxil fumarate) is a once-daily oral NtRTI for the treatment of chronic hepatitis B infection in adults. (U.S. and EU approval, 2008.) Cardiovascular Letairis® (ambrisentan) is a novel endothelin receptor antagonist (ERA) indicated for the once-daily treatment of PAH (WHO Group 1) in patients with WHO Functional Class II or III symptoms to improve exercise capacity and delay clinical worsening. (U.S. approval, 2007; E.U. approval, 2008.) Lexiscan® (regadenoson) injection is the first A2A adenosine receptor agonist approved by the FDA for use as a pharmacologic stress agent in radionuclide MPI studies. The product has been designed to target the A2A adenosine receptor, which is the adenosine receptor subtype responsible for coronary vasodilation. (U.S. approval, 2008.) Ranexa® (ranolazine) is an extended-release tablet for the treatment of chronic angina. Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors and angiotensin receptor blockers. (U.S. approval, 2006; U.S. expanded indication to include first-line treatment for chronic angina, 2008; E.U. approval, 2008.) Respiratory Tamiflu® (oseltamivir phosphate) is the first neuraminidase inhibitor tablet for the treatment and prevention of influenza A and B. Tamiflu was approved by the FDA for the treatment of influenza in October 1999 and for influenza prevention in November 2000. Tamiflu has been available in Europe since 2002. The product, which was developed by Gilead, is commercialized globally by Hoffmann-La Roche. Other AmBisome® (amphotericin B liposome for injection) is a treatment for life-threatening, systemic fungal infections in adults. (E.U. approval, 1990; U.S. approval, 1997.) Macugen® (pegaptanib sodium injection) is an injection for the treatment of neovascular age-related macular degeneration (also known as "wet" AMD), an eye disease that destroys central vision in elderly patients. This product is marketed in the United States by OSI Pharmaceuticals. (U.S. approval, 2004.) Vistide® (cidofovir injection) is an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS. (U.S. approval, 1996; E.U. approval, 1997.) Growing Worldwide Footprint Gilead has approximately 4,000 employees around the world. Corporate headquarters are located in Foster City, California. We also have additional operations in: North American Locations Foster City, CA (Headquarters) Palo Alto, CA San Dimas, CA Boulder, CO Durham, NC Seattle, WA Alberta, Canada Ontario, Canada International Locations United Kingdom (International Headquarters) Australia/New Zealand Austria Benelux Denmark France Germany Greece Ireland Italy Norway Portugal Spain Sweden Switzerland Turkey Corporate Responsibility As Gilead grows as a company, so do our responsibilities as a corporate citizen. We strive to play our part in expanding global access to our medications and to give back to the communities in which we operate. Gilead recognizes the urgent need for access to HIV medications worldwide, particularly in developing countries where the AIDS epidemic is devastating communities. We believe that the medicines we develop should be accessible to all patients who need them worldwide, regardless of income or location. To date, more than 400,000 patients in the developing world have received Gilead's therapies for the treatment of HIV. We are undertaking the following initiatives to help further expand access to our medicines in resource-limited settings: Gilead Access Program Since early 2003, we have operated an access program to provide Viread and Truvada at substantially reduced prices in many low- and middle-income countries. Local Manufacturing in Africa In 2005, Gilead entered into a non-exclusive partnership with South Africa-based Aspen Pharmacare, under which Aspen manufactures finished product for access program countries and distributes Gilead therapies throughout Africa. Partnerships with Indian Generic Manufacturers Gilead has signed non-exclusive licenses with multiple generic manufacturers in India. Under these agreements, our partners will produce high-quality generic versions of Viread in 95 resource-limited countries, which are home to 95 percent of the world's HIV-infected people. We expect that multiple manufacturers will ensure competitive pricing, thus promoting broad access to our products for patients in developing countries with HIV/AIDS. A Commitment to Research and Development Gilead has an active research and development program aimed at identifying new compounds for the treatment of life-threatening diseases (see Research section for more information). Ongoing Research Collaborations We are also working with academic, government and private sector partners to better understand the profile of our products in important areas such as pediatric HIV care, prevention of mother-to-child HIV transmission and pre-exposure prophylaxis. Patient Access in the United States Gilead supports a number of programs for eligible patients in the United States who do not have insurance, are underinsured or who otherwise need financial assistance. These programs include U.S. Advancing Access®, Atripla® Patient Access Program and Gilead™Solutions. The Gilead Foundation Since 2005, the Gilead Foundation has supported more than 80 domestic and international programs, many focused on building local capacity and improving health infrastructure in the developing world. The Foundation also supports disease awareness and education programs in the United States. Support for Community Organizations/Events Gilead provides unrestricted grants to non-profit organizations across the United States that advocate for people with serious, life-threatening diseases. In addition, the company sponsors national and local awareness-raising and fund-raising events, such as National HIV Testing Day, local AIDS and Liver Walks and California's AIDS LifeCycle, to name just a few. Please visit our Corporate Responsibility section for more information on Gilead's work in our communities. Leadership Following is a list of Gilead's Executive Committee. See the Leadership section for bios of these individuals as well as Gilead's Board of Directors. John C. Martin, PhD, Chairman and Chief Executive Officer John F. Milligan, PhD, President and Chief Operating Officer Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer Kevin Young, Executive Vice President, Commercial Operations Gregg H. Alton, Senior Vice President Kristen M. Metza, Senior Vice President, Human Resources Robin L. Washington, Senior Vice President and Chief Financial Officer More Information For more information about Gilead, its products or community involvement, please contact Gilead Public Affairs at +1 (650) 574-3000 or submit a media inquiry online.